CervoMed (CRVO) Competitors $8.41 -0.49 (-5.54%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVO vs. NGNE, CTNM, ACB, CADL, SCPH, TKNO, SOPH, NMRA, ALLO, and JBIOShould you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Neurogene (NGNE), Contineum Therapeutics (CTNM), Aurora Cannabis (ACB), Candel Therapeutics (CADL), scPharmaceuticals (SCPH), Alpha Teknova (TKNO), SOPHiA GENETICS (SOPH), Neumora Therapeutics (NMRA), Allogene Therapeutics (ALLO), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry. CervoMed vs. Its Competitors Neurogene Contineum Therapeutics Aurora Cannabis Candel Therapeutics scPharmaceuticals Alpha Teknova SOPHiA GENETICS Neumora Therapeutics Allogene Therapeutics Jade Biosciences CervoMed (NASDAQ:CRVO) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Does the media refer more to CRVO or NGNE? In the previous week, CervoMed had 2 more articles in the media than Neurogene. MarketBeat recorded 8 mentions for CervoMed and 6 mentions for Neurogene. CervoMed's average media sentiment score of 0.78 beat Neurogene's score of 0.00 indicating that CervoMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, CRVO or NGNE? CervoMed has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$9.74M7.98-$16.29M-$2.61-3.22NeurogeneN/AN/A-$75.14M-$4.31-6.66 Do analysts rate CRVO or NGNE? CervoMed presently has a consensus price target of $19.29, indicating a potential upside of 129.40%. Neurogene has a consensus price target of $46.17, indicating a potential upside of 60.75%. Given CervoMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe CervoMed is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60Neurogene 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 Do insiders and institutionals hold more shares of CRVO or NGNE? 25.2% of CervoMed shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 11.6% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CRVO or NGNE more profitable? Neurogene has a net margin of 0.00% compared to CervoMed's net margin of -290.72%. Neurogene's return on equity of -33.33% beat CervoMed's return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-290.72% -59.15% -53.64% Neurogene N/A -33.33%-30.34% Which has more risk and volatility, CRVO or NGNE? CervoMed has a beta of -0.84, meaning that its share price is 184% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. SummaryCervoMed beats Neurogene on 10 of the 15 factors compared between the two stocks. Get CervoMed News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVO vs. The Competition Export to ExcelMetricCervoMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.92M$3.38B$6.13B$10.61BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-3.2321.9385.8627.54Price / Sales7.98274.32540.53202.58Price / CashN/A47.1237.9261.55Price / Book1.8710.2012.986.78Net Income-$16.29M-$52.40M$3.30B$275.79M7 Day Performance2.90%6.22%4.73%2.99%1 Month Performance-15.93%15.91%9.96%9.50%1 Year Performance-34.42%31.98%84.61%35.97% CervoMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVOCervoMed3.7607 of 5 stars$8.41-5.5%$19.29+129.4%-32.6%$77.92M$9.74M-3.234News CoverageAnalyst ForecastShort Interest ↓NGNENeurogene1.2647 of 5 stars$23.09+3.4%$46.17+99.9%-48.7%$318.83M$930K-5.3690News CoverageAnalyst ForecastGap UpCTNMContineum Therapeutics2.1841 of 5 stars$11.08-2.4%$22.20+100.4%-29.2%$318.28MN/A-5.0431Analyst ForecastACBAurora Cannabis0.6341 of 5 stars$5.81+2.8%N/A+13.0%$317.65M$246.72M-30.581,130News CoveragePositive NewsAnalyst UpgradeCADLCandel Therapeutics2.596 of 5 stars$5.47-1.6%$20.00+265.6%+2.4%$305.22M$120K-7.9360Analyst ForecastSCPHscPharmaceuticals3.8098 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330Analyst ForecastHigh Trading VolumeTKNOAlpha Teknova2.0963 of 5 stars$5.65+0.2%$10.00+77.0%+7.3%$301.83M$37.74M-13.45240News CoverageAnalyst ForecastGap UpSOPHSOPHiA GENETICS2.3689 of 5 stars$4.05-8.0%$8.00+97.5%+32.2%$297.35M$65.17M-9.20520News CoverageAnalyst ForecastHigh Trading VolumeNMRANeumora Therapeutics2.4203 of 5 stars$1.89+3.3%$7.14+277.9%-86.8%$296.36MN/A-1.20108Analyst ForecastALLOAllogene Therapeutics2.7368 of 5 stars$1.38+3.8%$8.44+511.9%-46.4%$295.10M$20K-1.24310Analyst ForecastJBIOJade Biosciences2.8171 of 5 stars$9.14+3.2%$16.00+75.1%N/A$289.07MN/A-0.3020Analyst Forecast Related Companies and Tools Related Companies NGNE Alternatives CTNM Alternatives ACB Alternatives CADL Alternatives SCPH Alternatives TKNO Alternatives SOPH Alternatives NMRA Alternatives ALLO Alternatives JBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
